Kymera Therapeutics, Inc.
KYMR
$30.02
$0.270.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -240.88M | -223.86M | -167.47M | -157.85M | -154.59M |
| Total Depreciation and Amortization | 7.96M | 7.37M | 6.28M | 5.19M | 4.15M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.84M | 45.95M | 45.05M | 44.21M | 43.65M |
| Change in Net Operating Assets | -44.98M | -23.97M | -8.53M | 2.33M | 8.34M |
| Cash from Operations | -234.06M | -194.50M | -124.67M | -106.13M | -98.45M |
| Capital Expenditure | -5.90M | -12.84M | -23.53M | -31.79M | -37.87M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.95M | -391.24M | -430.17M | -203.71M | -177.43M |
| Cash from Investing | -24.86M | -404.08M | -453.69M | -235.50M | -215.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.56M | -1.58M | -358.00K | -57.00K | -39.00K |
| Issuance of Common Stock | 285.28M | 638.79M | 608.38M | 356.95M | 356.83M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.36M | -28.36M | -- | -- | -- |
| Cash from Financing | 255.35M | 608.85M | 608.02M | 356.90M | 356.79M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.56M | 10.27M | 29.66M | 15.27M | 43.04M |